ICR/Cyclacel scientists discover new cancer drug
Fadraciclib is a dual inhibitor of CDK2 and CDK9
Read More
Tag: CDK9
- Nxera Pharma reports positive results from phase 3 insomnia trial in South Korea
- Scottish Medicines Consortium becomes first in UK to adopt new precision gastric cancer treatment
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
